INTERNATIONAL JOURNAL OF SCIENTIFIC RESEARCH AND INNOVATIVE STUDIES
ISSN: 2820-7157
www.ijsrisjournal.com

August 2024 **Volume 3** **Number 4** **110-113**

Received Date: July 08, 2024 **Accepted Date:** July 29, 2024 **Published Date:** August 01, 2024

Available Online at https://www.ijsrisjournal.com/index.php/ojsfiles/article/view/289

https://doi.org/10.5281/zenodo.14549331

Comprehensive Review of the Genetic Polymorphism of Schistosoma mansoni and Drug Resistance: Human vs. Intermediate Host Perspective

Zinab Ahmed Sonpul[1], Amal Radhi Mohammed Al Hazeem[2], Hossah Ahmed H Almeiter[3], Eman Ali Hussan Abandi [1], Amal Abdel Raoof Al Mahozi[4], Gehan Abdulateef Al Abdullh[4], Yasser Ali Abdulhadi Bujbarah[5],, Amal Abdulmunam Alkhunizi[6], Abdulaziz Saad Aldossary[7], Faisal Sadiq Alessa[8], Afrah Haydir Alsabiy[9], Moayad Ahmed Taher Albutyan[10], Jalela Makki Alkhabbaz[2], Sherehan Mohammed Albkhtan [11], Edrees Salman Ali Almatter[12]

1.Safwa GeneralGeneral
2.Qatif central hospital
3.Dhahran eye specialist hospital
4.Comprehensive Screening Center
5.King fahad phc
6.Maternity and children hospital
7.Al Oyoun City Hospital
8.Dammam health network
9. AlFaisal PHC
10.Primary Health Care Center Shoba Almubarraz
11.King fahad hospital hofuf
12.Primary health care

ABSTRACT

Schistosoma mansoni, the causative agent of intestinal schistosomiasis, exhibits substantial genetic polymorphism, contributing to its adaptability and resistance to praziquantel (PZQ), the mainstay treatment for schistosomiasis. This review explores the genetic mechanisms underlying S. mansoni diversity, emphasizing its role in drug resistance and interactions with human (definitive) and snail (intermediate) hosts. Genetic variation in S. mansoni is driven by sexual reproduction, recombination, and host-parasite co-evolution, with key contributions from microsatellites, mitochondrial DNA, and single nucleotide polymorphisms (SNPs). While human immune responses and PZQ administration impose selective pressures, snail hosts shape genetic compatibility and transmission dynamics. Evidence suggests that high genetic diversity enhances immune evasion and influences drug susceptibility, complicating control efforts. Comparative analysis of human and snail host influences reveals distinct yet interconnected drivers of parasite evolution. Integrative strategies combining genomic surveillance, snail control, and novel therapeutics are essential for managing drug resistance and sustaining schistosomiasis control efforts.

1. Introduction

Schistosoma mansoni, a parasitic trematode causing intestinal schistosomiasis, affects millions worldwide, primarily in sub-Saharan Africa and South America(1). Its lifecycle alternates between humans (definitive host) and freshwater snails (Biomphalaria spp.) as intermediate hosts. The parasite's genetic diversity plays a pivotal role in its adaptability to environmental pressures and resistance to praziquantel (PZQ), the frontline treatment for schistosomias(2). A deeper understanding of the genetic mechanisms influencing host-parasite interactions and drug resistance is essential for effective disease control.

2. Genetic Polymorphism in Schistosoma mansoni

Genetic polymorphism underpins the adaptability of S. mansoni to its hosts and environmental challenges. This diversity results from sexual reproduction, recombination, and host-parasite co-evolution Genetic diversity in Schistosoma mansoni populations: implications for control.(3).

2.1 Mechanisms of Genetic Variation

- **Microsatellite Markers**: Microsatellites are widely used to assess genetic diversity and structure in S. mansoni populations(4).
- **Mitochondrial DNA (mtDNA)**: mtDNA analysis has revealed gene flow and evolutionary relationships among geographically distinct populations(5).
- **Single Nucleotide Polymorphisms (SNPs)**: SNP studies have linked genetic variation to traits such as drug resistance and host specificity(6).

2.2 Implications of Polymorphism

High genetic diversity within S. mansoni populations facilitates:

- Enhanced adaptability to human immune responses (7)
- Variability in drug susceptibility, affecting treatment outcomes.

3. Drug Resistance in Schistosoma mansoni

Resistance to praziquantel has been documented in several regions, raising concerns about its long-term efficacy Schistosomiasis control: Pre(8)sent and future.(9)

3.1 Mechanisms of Resistance

- **Selection Pressure**: Frequent use of PZQ in mass drug administration (MDA) campaigns promotes the selection of resistant genotypes.
- **Mutations in Drug Target Genes**: Resistance is associated with mutations in calcium channel genes targeted by PZQ.
- **Genetic Bottlenecks**: Reduced genetic diversity in isolated populations due to MDA campaigns may amplify resistance traits(10).

3.2 Evidence from Studies

- Studies in Senegal and Egypt identified S. mansoni strains with reduced susceptibility to PZQ, emphasizing the importance of monitoring resistance markers
- SNP analyses have identified candidate resistance genes in experimental and field populations.

4. Host-Specific Dynamics

The lifecycle of S. mansoni involves dual host systems, with selective pressures imposed by both human and snail hosts shaping genetic diversity.

4.1 Human Hosts

Humans exert selective pressures through:

- **Immune Responses**: Genetic diversity in S. mansoni enables immune evasion, promoting the survival of specific genotypes(11).
- **Drug Pressure**: PZQ treatment applies strong selective pressure, driving the evolution of resistant strains

4.2 Intermediate Hosts (Snails)

Snail hosts influence S. mansoni polymorphism through:

- **Genetic Compatibility**: Snail genetic diversity determines compatibility with S. mansoni strains, affecting transmission dynamics.
- **Population Bottlenecks**: Low genetic diversity in snail populations may constrain S. mansoni genetic variability.

5. Comparative Analysis: Human vs. Intermediate Hosts

Table 1: Human vs. Intermediate Hosts

Aspect	Human Host	Intermediate Host (Snails)
Selective Pressure	Immune system and drug treatments	Genetic compatibility and environment
Genetic Diversity	Higher, driven by immune evasion	Lower, constrained by snail genetics
Drug Resistance	More pronounced due to MDA	Indirect via parasite adaptation
Polymorphism Impact	Affects virulence and drug efficacy	Influences transmission dynamics

6. Implications for Control Strategies

- **Integrated Approaches**:
  - Combine MDA with snail control to limit transmission and mitigate drug resistance risks.
- **Genomic Surveillance**:
  - Implement whole-genome sequencing to track resistance markers and monitor population dynamics.
- **Novel Drug Development**:
  - Design multi-target drugs to address the genetic variability of S. mansoni

Conclusion

The genetic polymorphism of Schistosoma mansoni significantly impacts its adaptability, virulence, and resistance to praziquantel. The selective pressures exerted by human and snail hosts shape this diversity, influencing treatment efficacy and transmission. Continued research into host-parasite interactions and genomic surveillance is essential for sustainable schistosomiasis control.

References

1. Kamdem SD, Moyou-Somo R, Brombacher F, Nono JK. Host regulators of liver fibrosis during human schistosomiasis. Vol. 9, Frontiers in Immunology. 2018.

2. Li X, Weth O, Haimann M, Möscheid MF, Huber TS, Grevelding CG. Rhodopsin orphan GPCR20 interacts with neuropeptides and directs growth, sexual differentiation, and egg production in female Schistosoma mansoni . Microbiol Spectr. 2024;12(1).

3. Gower CM, Gouvras AN, Lamberton PHL, Deol A, Shrivastava J, Mutombo PN, et al. Population genetic structure of Schistosoma mansoni and Schistosoma haematobium from across six sub-Saharan African countries: Implications for epidemiology, evolution and control. Acta Trop. 2013;128(2).

4. van den Broeck F, Maes GE, Larmuseau MHD, Rollinson D, Sy I, Faye D, et al. Reconstructing colonization dynamics of the human parasite schistosoma mansoni following anthropogenic environmental changes in Northwest Senegal. PLoS Negl Trop Dis. 2015;9(8).

5. Agola LE, Mburu DN, DeJong RJ, Mungai BN, Muluvi GM, Njagi ENM, et al. Microsatellite typing reveals strong genetic structure of Schistosoma mansoni from localities in Kenya. Infect Genet Evol. 2006;6(6).

6. Liang YS, Dai JR, Zhu YC, Coles GC, Doenhoff MJ. Genetic analysis of praziquantel resistance in Schistosoma mansoni. Southeast Asian J Trop Med Public Health. 2003;34(2).

7. Qi L, Cui JA. A schistosomiasis model with praziquantel resistance. Discret Dyn Nat Soc. 2013;2013.

8. Gardner P, Rohde JE, Majumdar MB, Rutherford GW, Mahanjane AE, Long R, et al. [Not Available]. Hum Reprod.

2014;

9. Jordan P, Rosenfield PL. Schistosomiasis control: past, present, and future. Annu Rev Public Health. 1983;4.

10. Webster JP, Gower CM, Norton AJ. Evolutionary concepts in predicting and evaluating the impact of mass chemotherapy schistosomiasis control programmes on parasites and their hosts. Evol Appl. 2008;1(1).

11. Molehin AJ. Current Understanding of Immunity Against Schistosomiasis: Impact on Vaccine and Drug Development . Res Rep Trop Med. 2020 Nov;Volume 11:119–28.